Citation Impact
Citing Papers
Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy
2010
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
2012
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
2014 Standout
CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis
2014
Advances in stem cell mobilization
2014
Leukocyte lipid bodies regulation and function: Contribution to allergy and host defense
2006
Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells
2013
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Neutrophils at work
2014 Standout
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Advances in stem cell mobilization
2012
The MAGE protein family and cancer
2015
Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells
2011
Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy
2007
Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines
2015 StandoutNobel
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole
2012
Thematic review series: Adipocyte Biology. The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis
2007 Standout
A within-trial cost-effectiveness analysis of primary care referral to a commercial provider for weight loss treatment, relative to standard care—an international randomised controlled trial
2012 Standout
Keynote review: The adipocyte as a drug discovery target
2005
Pathogenesis and treatment of renal failure in multiple myeloma
2008
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
2013
Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association
2018
Signaling through cyclin D-dependent kinases
2013
Adipose Tissue as an Endocrine Organ
2004 Standout
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
2012
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
2012
Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
2009
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
Adipose Tissue-Derived Factors: Impact on Health and Disease
2006
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
2014
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model
2008
Fat and Beyond: The Diverse Biology of PPARγ
2008 Standout
The Multifaceted Roles of Adipose Tissue—Therapeutic Targets for Diabetes and Beyond: The 2015 Banting Lecture
2016
Combination therapy in combating cancer
2017 Standout
Proteasome Inhibition Alleviates SNARE-Dependent Neurodegeneration
2012 StandoutNobel
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
2015 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
Multiple Myeloma
2011 Standout
Oncogenic cancer/testis antigens: prime candidates for immunotherapy
2015
Global burden of heart failure: a comprehensive and updated review of epidemiology
2022 Standout
Works of David Jayabalan being referenced
The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development
2008
MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin
2011
Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization
2013
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma
2007
Lenalidomide‐induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment‐naïve patients undergoing front‐line lenalidomide and dexamethasone therapy
2007
Clarithromycin (Biaxin)‐lenalidomide‐low‐dose dexamethasone (BiRd) versus lenalidomide‐low‐dose dexamethasone (Rd) for newly diagnosed myeloma
2010
The Adipocyte as an Important Target Cell for Trypanosoma cruzi Infection
2005
Targeting Cdk4/6 in Combination Therapy Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma through Synergistic Mitochondria Depolarization.
2007
High-Yield of CD34+ Cells With Bortezomib-Based Mobilization Regimen Is Associated With Specific Genomic Expression Patterns, Decrease in SDF-1 Plasma Levels and Up-Regulation of CXCR4 in Multiple Myeloma (MM) Patients
2011
Targeting Cdk4/6 in combination therapy of chemoresistant multiple myeloma
2008
Selective Inhibition of CDK4 and CDK6 Primes Chemoresistant Myeloma Cell for Cytotoxic Killing through Induction of Cell Cycle-Coupled Mitochondrial Dysfunction and Apoptosis
2008
Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4
2012
Lenalidomide Targets Myeloma Cells Preferentially During Prolonged Early G1 Arrest but Not Synchronization Into S Phase by Selective and Reversible Inhibition of CDK4/CDK6 through Loss of IRF-4
2010
Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).
2005
Induction of Metabolic Impairment In Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition Sensitizes Myeloma Cells for Proteasome Inhibitor Killing During Subsequent S Phase Synchronization
2010